Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

April
27
2026

Basal Cell Carcinoma vs. Squamous Cell Carcinoma: What’s the Difference?

Melanoma and non-melanoma are two primary categories of skin cancer. Each presents different symptoms and treatment options. Within the non-melanoma skin cancer – sometimes referred to as NMSC – category, the two most common types…

February
09
2023

Sensus Healthcare Fourth Quarter 2022 Financial Results Include Quarterly Revenues of $13.1 Million

Full-year revenues increased 65% to $44.5 million Investments in technology and staff position Sensus for growth in 2023 and beyond Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Feb. 09, 2023…

February
01
2023

Sensus Healthcare to Host Fourth Quarter 2022 Financial Results and Business Update Conference Call on February 9, 2023

BOCA RATON, Fla., Feb. 01, 2023 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference…

January
09
2023

Sensus Healthcare Announces Senior Management Appointments and Promotions

BOCA RATON, Fla, Jan. 09, 2023 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, is pleased to announce the…

January
05
2023

Sensus Healthcare Announces Preliminary Fourth Quarter 2022 Revenues

Fourth quarter revenues to exceed $13 million; full year revenues to exceed $44 million, representing growth of 60% BOCA RATON, Fla, Jan. 05, 2023 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing…

Archives
Archives

IN THE NEWS

CEO Joseph Sardano on Coding for Superficial Radiation Therapy